ERBB2 and neoplasm: Tumor tissue specimens are the main source for evaluating HER2 status in patients with GC17–19,however, a positive HER2 status can be misdiagnosed as negative in patients with GC, when the diagnosis is based on tissue biopsy; this is due to tumor heterogeneity18,28.